277 related articles for article (PubMed ID: 21733826)
1. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure.
Chapman CJ; Murray A; McElveen JE; Sahin U; Luxemburger U; Türeci O; Wiewrodt R; Barnes AC; Robertson JF
Thorax; 2008 Mar; 63(3):228-33. PubMed ID: 17932110
[TBL] [Abstract][Full Text] [Related]
3. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1.
Türeci O; Mack U; Luxemburger U; Heinen H; Krummenauer F; Sester M; Sester U; Sybrecht GW; Sahin U
Cancer Lett; 2006 May; 236(1):64-71. PubMed ID: 15992994
[TBL] [Abstract][Full Text] [Related]
4. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.
Chapman CJ; Healey GF; Murray A; Boyle P; Robertson C; Peek LJ; Allen J; Thorpe AJ; Hamilton-Fairley G; Parsy-Kowalska CB; MacDonald IK; Jewell W; Maddison P; Robertson JF
Tumour Biol; 2012 Oct; 33(5):1319-26. PubMed ID: 22492236
[TBL] [Abstract][Full Text] [Related]
5. Clinical validation of an autoantibody test for lung cancer.
Boyle P; Chapman CJ; Holdenrieder S; Murray A; Robertson C; Wood WC; Maddison P; Healey G; Fairley GH; Barnes AC; Robertson JF
Ann Oncol; 2011 Feb; 22(2):383-9. PubMed ID: 20675559
[TBL] [Abstract][Full Text] [Related]
6. Serum anti-p53 antibodies in patients with lung cancer.
Mack U; Ukena D; Montenarh M; Sybrecht GW
Oncol Rep; 2000; 7(3):669-74. PubMed ID: 10767388
[TBL] [Abstract][Full Text] [Related]
7. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance and diagnostic value of Survivin autoantibody in non-small cell lung cancer patients].
Ma L; Yue W; Zhang L; Wang Y; Zhang C; Yang X
Zhongguo Fei Ai Za Zhi; 2010 Jul; 13(7):706-12. PubMed ID: 20673487
[TBL] [Abstract][Full Text] [Related]
9. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice.
Jett JR; Peek LJ; Fredericks L; Jewell W; Pingleton WW; Robertson JF
Lung Cancer; 2014 Jan; 83(1):51-5. PubMed ID: 24268382
[TBL] [Abstract][Full Text] [Related]
10. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
Doseeva V; Colpitts T; Gao G; Woodcock J; Knezevic V
J Transl Med; 2015 Feb; 13():55. PubMed ID: 25880432
[TBL] [Abstract][Full Text] [Related]
11. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
12. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer.
Du Q; Yu R; Wang H; Yan D; Yuan Q; Ma Y; Slamon D; Hou D; Wang H; Wang Q
Clin Respir J; 2018 Jun; 12(6):2020-2028. PubMed ID: 29356386
[TBL] [Abstract][Full Text] [Related]
13. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies against tumor-associated antigens in the early detection of lung cancer.
Dai L; Tsay JC; Li J; Yie TA; Munger JS; Pass H; Rom WN; Zhang Y; Tan EM; Zhang JY
Lung Cancer; 2016 Sep; 99():172-9. PubMed ID: 27565936
[TBL] [Abstract][Full Text] [Related]
15. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
[TBL] [Abstract][Full Text] [Related]
16. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer.
Wang W; Guan S; Sun S; Jin Y; Lee KH; Chen Y; Wei J
Tumour Biol; 2014 May; 35(5):4901-5. PubMed ID: 24453033
[TBL] [Abstract][Full Text] [Related]
17. Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers.
Cioffi M; Vietri MT; Gazzerro P; Magnetta R; D'Auria A; Durante A; Nola E; Puca GA; Molinari AM
Lung Cancer; 2001; 33(2-3):163-9. PubMed ID: 11551411
[TBL] [Abstract][Full Text] [Related]
18. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.
Tang ZM; Ling ZG; Wang CM; Wu YB; Kong JL
PLoS One; 2017; 12(7):e0182117. PubMed ID: 28750095
[TBL] [Abstract][Full Text] [Related]
19. Seven tumor-associated autoantibodies as a serum biomarker for primary screening of early-stage non-small cell lung cancer.
Chen P; Lu W; Chen T
J Clin Lab Anal; 2021 Nov; 35(11):e24020. PubMed ID: 34555232
[TBL] [Abstract][Full Text] [Related]
20. Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group.
Myšíková D; Adkins I; Hradilová N; Palata O; Šimonek J; Pozniak J; Kolařík J; Skallová-Fialová A; Špíšek R; Lischke R
J Thorac Oncol; 2017 Feb; 12(2):249-257. PubMed ID: 27793776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]